More: 30th Annual San Antonio Breast Cancer Symposium (SABCS)

Refining First-line Treatment for Metastatic Breast Cancer CME

San Antonio, Texas

Author Information and Disclosures

This activity is not sanctioned by, nor a part of, the San Antonio Breast Cancer Symposium.

Release Date: January 15, 2008; Valid for credit through January 15, 2009

Credits Available
Physicians - maximum of 0.5 AMA PRA Category 1 Credit(s)™ for physicians

The content of this CME activity, "Refining First-line Treatment for Metastatic Breast Cancer" was developed by the faculty.

To participate in this activity: 1) review the target audience, learning objectives and author disclosures, 2) study the education content 3) answer the posttest and evaluation 4) view/print certificate View details

Contents of This CME Activity

Legal Disclaimer

The materials presented here do not reflect the views of Medscape or the companies providing unrestricted educational grants. These materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. All readers or continuing education participants should verify all information and data before treating patients or employing any therapies described in this educational activity.

The materials presented here were prepared by independent authors under the editorial supervision of Medscape and do not represent a publication of the San Antonio Breast Cancer Symposium. These materials and the related activity are not sanctioned by the San Antonio Breast Cancer Symposium or the commercial supporter of the conference and do not constitute an official part of that conference.

Copyright © 2008 Medscape.
Roche
Learning Objectives

Upon completion of this activity, participants will be able to:

  1. Describe clinical challenges in treatment of metastatic breast cancer
  2. Review current first-line treatment options for patients with metastatic breast cancer
  3. Discuss findings from clinical trials exploring newer first-line treatment options, including oral regimens, novel biologics, and new chemotherapy classes
  4. Outline future directions for first-line treatment of metastatic breast cancer
Authors Disclosures

Hope S. Rugo, MD
Disclosure: Hope S. Rugo, MD, has disclosed that she has received grants for clinical research from Bristol-Myers Squibb, Genentech, GlaxoSmithKline, Novartis, Pfizer, and Roche, and that she has served on the speakers' bureau for Genomic Health.


Harold J. Burstein, MD, PhD
Disclosure: Harold J. Burstein, MD, PhD, has disclosed no relevant financial relationships.


Maura Dickler, MD
Disclosure: Maura Dickler, MD, has disclosed that she has served as a consultant to Genentech, Novartis, and Pfizer.


Margie Miller
Disclosure: Margie Miller has disclosed no relevant financial relationships.


Jill W. Chamberlain
Disclosure: Jill W. Chamberlain has disclosed no relevant financial relationships.
 
Medscape
Medscape, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Medscape, LLC designates this educational activity for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Contact This Provider

All material on this website is protected by copyright, Copyright © 1994-2008 by Medscape. This website also contains material copyrighted by 3rd parties.